Anti-leucine-rich glioma-inactivated 1 encephalitis with manic symptoms as the initial manifestation

Related Experiment Video

Updated: Feb 18, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K

Tsung-Han Tu1, Yee-Lam E Chan1, Ya-Mei Bai1,2

  • 11 Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.

The Australian and New Zealand Journal of Psychiatry
|November 18, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.8K

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

666
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
666
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

732
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
732

Articles linked to this work by shared authors, journal, and citation graph.

Low-dose ketamine modulates brain entropy in treatment-resistant depression: Results from two neuroimaging clinical trials.

Journal of affective disorders·2026

Effect of a project achievement-oriented Quality Control Circle on traditional Chinese medicine nursing outcomes in elderly patients with distal radius fractures: A retrospective comparative study.

Medicine·2026

Adaptation and validation of the Wylie cephalometric analysis for three-dimensional assessment of canine occlusion in Labrador retrievers.

Frontiers in veterinary science·2026

Symptom-level and network analyses of ketamine treatment in treatment-resistant depression: A pooled analysis of two randomized controlled trials.

Progress in neuro-psychopharmacology & biological psychiatry·2026

Childhood Trauma Clusters, Klotho, Matrix Metalloproteinase-9, and Cognitive Function in Adolescents with Major Affective Disorders.

Neuropsychobiology·2026

Antidepressant composition change before bipolar disorder diagnosis among patients initially diagnosed with major depressive disorder.

Journal of affective disorders·2026

Assisted dying in Canada has lessons for psychiatrists in Australia and New Zealand-just not the ones you might think.

The Australian and New Zealand journal of psychiatry·2026

Mortality in borderline personality disorder: A 13-year nation-wide retrospective cohort study.

The Australian and New Zealand journal of psychiatry·2026

Time to face the music: Mental health measures are failing us.

The Australian and New Zealand journal of psychiatry·2026

Towards equity in Aboriginal and Torres Strait Islander mental health: Policy priorities across Medicare, telehealth and the National Disability Insurance Scheme.

The Australian and New Zealand journal of psychiatry·2026

Disease-modifying interventions in psychiatry.

The Australian and New Zealand journal of psychiatry·2026

Psychosocial disability in Australia: Prevalence, functional severity and population projections to 2060 from repeated cross-sectional population surveys.

The Australian and New Zealand journal of psychiatry·2026

Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature.

The American Journal of dermatopathology·2026

Adjunctive infliximab for paradoxical reactions and immune reconstitution inflammatory syndrome in central nervous system tuberculosis: a scoping review.

Expert review of anti-infective therapy·2026

Human leukocyte antigens and permanent hypothyroidism after subacute thyroiditis.

Postgraduate medicine·2026

High-Titer Antinuclear Antibody Defines a Distinct IgG4-Related Disease Subset With Predilection for Lung and Kidney Involvement.

Journal of immunology research·2026

Isolated Rosai-Dorfman disease of the cerebellum: A rare presentation of a histiocytic disorder mimicking a posterior fossa neoplasm.

Clinical neuropathology·2026

A fibril-selective single-domain antibody targets pathogenic amyloid-β assemblies and protects human neurons.

iScience·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us